Targeting IL-17A and IL-17 receptors using antibodies (e.g., the IL-17 inhibitor secukinumab and the IL-17R inhibitor brodalumab) has achieved remarkable success in treating psoriasis (58). This evidence concerns the gene IL17A and psoriasis.